Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular Pressure

NCT06441643 is registered in ClinicalTrials.gov with Alcon Research as lead sponsor.

NCT NCT06441643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Two-Stage, Double-Masked, Randomized, Multi-Center, Controlled, Dose-Response Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-17043 and PG043 (AR-17043/Latanoprost) Ophthalmic Solutions in Subjects With Elevated Intraocular Pressure
Lead sponsor
Alcon Research
Phase
Phase 2
Overall status
Completed
Start date
September 4, 2024
Completion date
November 14, 2025
Enrollment
426 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open angle glaucoma